Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SOLIRIS (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
SOLIRIS
Date registered
Evaluation commenced
Decision date
Approval time
115 working days (255)
Active ingredients
eculizumab
Registration type
EOI
Indication
SOLIRIS (intravenous infusion) is indicated for the treatment of patients with:
- Paroxysmal Nocturnal Haemoglobinuria (PNH) to reduce haemolysis.
- atypical Haemolytic Uraemic Syndrome (aHUS).
- Adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive.
SOLIRIS is not intended for acute treatment of a NMOSD relapse.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.